BioSpace News Archive

Nabriva Therapeutics plc announced that the Centers for Medicare and Medicaid Services confirmed its preliminary decision to assign a permanent product-specific Healthcare Common Procedure Coding System J-code for XENLETA™ 150 mg injection. The new billing code, J0691 Injection, will become effective July 1, 2020 and will replace the C Code, C9054.

Microbix Biosystems Inc. and Oneworld Accuracy announce a strategic collaboration to provide a global external quality assessment program to support clinically-effective COVID-19 testing.

Respiratory diseases including asthma, chronic obstructive pulmonary disorder, acute respiratory infections, tuberculosis, and lung cancer are some of the major chronic diseases affecting millions of people around the world.

The vendor landscape of the antiviral drugs market is consolidated with the dominated of few players, says Transparency Market Research.

The quest of the healthcare industry to offer customization to patients has played a key role in the growth of the global disposable oxygen masks market.

Vapotherm, Inc. announced that the U.S. Food and Drug Administration recently granted Breakthrough Device Designation for the Company’s Oxygen Assist Module.

Breakthrough Therapy Designation and Submission based on positive Phase III JAVELIN Bladder 100 study results

ProMIS Neurosciences, Inc. announced that the journal Neurology will publish AAN abstracts of data that demonstrate the strength of its antibody programs for Parkinson’s disease/alpha-synuclein and amyotrophic lateral sclerosis /TDP-43.

ViewRay, Inc. announced details relating to the release of its first quarter 2020 financial results..

The grant aimed for development of antiviral PPE and long-acting surface coating to protect frontline personnel and reduce viral transmission.